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ABSTRACT
Introduction: Our main aim was to assess the
level of persistence and adherence to therapy
with glucagon-like peptide-1 (GLP-1) receptor
agonists in type 2 diabetes mellitus (T2DM)
patients in the United Kingdom (UK) and
Germany, also by comparing once- (OD) with
twice-a-day (BID) therapy.
Methods: We used two large retrospective
datasets: a German claims dataset and the UK
General Practitioner (GP)-based Clinical
Practice Research Datalink (CPRD) dataset
(2010–2012). All continuously insured T2DM
patients with at least one outpatient/inpatient
T2DM diagnosis were observed starting with the
first prescription of a GLP-1 receptor agonist.
Non-persistence (NP) was defined as treatment
gap[90 days. Non-adherence (NA) was defined
as medication possession ratio\80%, calculated
during a period in which a patient continued
therapy (no treatment gap[90 days) only.
Results: In the UK sample, 1905 T2DM patients
started a treatment with GLP-1 receptor
agonists (mean age: 55.5 years, 47.2% female).
In the German sample, 1627 T2DM patients
started a treatment with GLP-1 receptor
agonists (mean age: 56.6 years, 51.4% female).
Percentage of NP patients after 12 months was
29.5% in the UK and 36.4% in the German
sample. In both countries, a BID treatment was
associated with a higher probability to
discontinue a treatment with GLP-1 receptor
agonists earlier than an OD treatment (hazard
ratio [HR] = 1.431 in UK and HR = 1.314 in
Germany). The percentages of patients
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considered NA were 20.2%/20.0%/20.5% (all/
OD/BID) for the UK sample, and 19.9%/19.2%/
21.8% (all/OD/BID) for the German sample.
Conclusion: NP and NA to treatment with
GLP-1 receptor agonists in both UK and
Germany appear to be similar. Persistence to
OD treatment is higher than to BID treatment
in both the UK and Germany.
Keywords: GLP-1 receptor agonists;
Non-adherence; Non-persistence; Type 2
diabetes mellitus
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is amongst the
most common chronic diseases and is a growing
worldwide epidemic [1]. The primary goal of
diabetes treatment is to control blood glucose
levels [2, 3]. Treatment guidelines recommend
metformin as first-line therapy, followed by
several options as second-line agents,
including sulfonylureas (SU),
thiazolidinediones, alpha-glucosidase
inhibitors, dipeptidyl peptidase-4 (DPP-4)
inhibitors, basal insulin, sodium/glucose
cotransporter 2 inhibitors, and now also,
glucagon-like peptide-1 (GLP-1) receptor
agonists [2–4]. In Germany and the United
Kingdom (UK), there are currently six GLP-1
receptor agonists available, twice-daily (BID)
exenatide, once-daily (OD) liraglutide, OD
lixisenatide, once-weekly exenatide,
once-weekly albiglutide and once-weekly
dulaglutide which have all been shown to be
both effective and safe options for T2DM
treatment after metformin failure [5–7].
However, despite the number and variety of
available T2DM treatment options, it is known
from several real-world studies that reaching
target glucose levels remains a challenge for
many patients [8–10]. One of the reasons for
this may be non-persistence (NP—
discontinuation of a prescribed therapy), and/
or non-adherence (NA) (continued use of
therapy, but not as prescribed). Several studies
have found a high level of both NP and NA with
regards to anti-diabetic therapy [11–16] and
confirmed worse diabetes-related outcomes
associated with NP/NA [17–20]. Much less is
known about the level of persistence/adherence
to therapy with GLP-1 receptor agonists. Three
previous US analyses reported 12-month
medication possession ratios (MPRs) of 68%
for BID GLP-1 [21], 69.7% for OD GLP-1 and
64.4% for BID GLP-1 [22], or 78.3% for
once-weekly GLP-1, compared to 50.0% for
BID GLP-1 and 68.3–76.1% for OD GLP-1 [23],
the only known European-based study reported
a 12-month therapy discontinuation rate of
32.2% for BID therapy with GLP-1 receptor
agonists only [24]. Consequently, there is
limited real-world data from European T2DM
patients about the persistence and adherence to
therapy with GLP-1 receptor agonists.
Therefore, our aim was to use two large
European datasets, to (1) assess the level of
persistence and adherence to therapy with
GLP-1 receptor agonists in T2DM patients in
UK and Germany, and compare OD with BID
therapy and (2) to identify any factors that may
explain early discontinuation of therapy with
GLP-1 receptor agonists in the first year of
therapy as well as to assess outcomes possibly
associated with early discontinuation of therapy.
METHODS
Our study had access to two large retrospective
datasets: a German claims dataset provided by
one large sickness fund (AOK PLUS; 2.7 million
insured; http://www.aokplus.de) and the UK
General Practitioner (GP)-based Clinical Practice
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Research Datalink (CPRD) database (longitudi-
nal data covering about 4.4 million patients
treated by about 500 GPs; http://www.cprd.com;
accessed Jan 2015). As far as data available in the
two datasets allowed, we used the same
methodology for each of the database analyses.
T2DM Samples
This was a retrospective non-interventional
cohort analysis based on anonymized data for
the calendar years 2010–2012 (separate
analyses; no linking of country data). All
T2DM patients [at least one outpatient T2DM
diagnosis (ICD E11.- or CPRD read codes which
are available from the authors upon request)
and/or at least one inpatient T2DM diagnosis
before index date] who were enrolled
continuously in the databases from 01/01/
2010 until the end of the observational period
were included in the analysis; death during the
observational period was the only exception to
the continuous enrolment requirement.
We analyzed persistence/adherence to therapy
with GLP-1 receptor agonists in common use
during the study period [BID exenatide
(Anatomical Therapeutic Chemical [ATC] code:
A10BX04), OD liraglutide (ATC code: A10BX07)].
We excluded exenatide in its once-weekly
formulation, as it was introduced late in the
study period and rarely used. In addition, we did
not observe therapy with lixisenatide, albiglutide,
and dulaglutide because these agents were
approved after end of 2012.
Analysis was done based on treatment-naı¨ve
patients only, defined as no prescription of
medication of interest in the 6 months before
first observed GLP-1 prescription. However,
anti-diabetic medication other than the
medication of interest was possible. The start
of therapy with GLP-1 receptor agonists was
between 01/07/2010 and 30/06/2011 with date
of the first GLP-1 prescription defining the
index date. A 6-month pre-index period was
used to determine eligibility for inclusion and a
18-month post-index period was used for the
persistence/adherence analysis (Fig. 1).
Assessment of Treatment Persistence
Our analysis was based on the days’ supply of
the observed prescriptions. To enable
comparability between databases, and because
of incomplete data with regards to prescribed
days of supply, we assumed that the prescribed
daily dosage was equal to the WHO defined
daily dosage per medication [25].
NP was defined as a treatment gap of more
than 90 days (sensitivity analysis: 180 days). We
reported percentage of patients that could be
classified as non-persistent at 3, 6, and 12 months
after index date. In the German analysis,
hospitalizations periods were taken out from
observed days because drug’s supply was
assumed to be provided by hospitals during
these days. In contrast, in the UK analysis,
information about hospitalization periods was
not available for all patients. Furthermore, both in
the UK and German analyses, stockpiling was
included by assuming that, in case there were
overlapping medications, the previous supply was
taken fully before the new supply was initiated.
Assessment of Treatment Adherence
Treatment adherence was analyzed in two ways.
First, for the overall sample which included
those patients who may have discontinued
therapy during our preset observation period
and those continuing their therapy, we analyzed
the overall MPR, defined as number of days’
supply received during the whole observational
period of 12 months after index date, divided by
the number of days in the evaluation period:
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In our second NA analysis, we explored
adherence only for the period in which a
patient continued therapy (no treatment gap
[90 days; Fig. 1):
Adherence was reported in three ways, first as
mean MPR, second as percentage of patients with
a MPR\80% and third, in a sensitivity analysis, as
percentage of patients with a MPR\70/90%.
Fig. 1 Methodology of analysis. The ﬁgure shows how reference period, index date and observational period have been
deﬁned. GLP-1 glucagon-like peptide-1, MPR medication possession ratio
MPR ¼ Number of days
0 supply received during observational period
365 days  hospitalisation days GERð Þ  days after death
MPR ¼ Number of days
0 supply received during persistent period
Days between first and last prescription without any treatment gaps [90
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Assessment of Variables Predicting NP
to Therapy with GLP-1 Receptor Agonists
Assessment of potential factors predicting
12-month NP to therapy with GLP-1 receptor
agonists (treatment gap [90 days) was done
using a multivariable Cox regression estimation
with time to therapy discontinuation as
dependent variable. Only patients receiving
either an OD or BID therapy with GLP-1
receptor agonists were included, switchers
between different treatment regimes with
GLP-1 receptor agonists were excluded. As
initial independent variables, age (at 31/12/
2009), gender, Charlson Comorbidity Index
(CCI) based on diagnoses in the 6 months
before the index date and excluding age as
factor, OD versus BID treatment regimen with
GLP-1 receptor agonists, any anti-diabetic
medication in the 180 days before index date
(yes/no), number of received anti-diabetic
medications (consideration of SU’s, DPP-4
inhibitors, metformin and any insulin) in the
180 days before/after index date, and at least
one visit to a diabetologist in the 6 months
before the index date (yes/no) were included. In
the UK CPRD analysis, a visit to a Diabetologist
was assumed to have taken place if a NHS code
for ‘‘endocrinology’’ or ‘‘diabetic nurse
specialist’’ was included.
Assessment of NP-Related Outcomes
For T2DM patients newly initiating therapy
with GLP-1 receptor agonists (no GLP-1
prescriptions in the previous 180 days before
index date), we analyzed three diabetes-related
outcomes which may be associated with NP
([90 days gap; 6-month NP): (1) insulin
initiation in a subgroup of insulin-naı¨ve T2DM
patients, (2) occurrence of any acute
hospitalizations with T2DM as main diagnosis,
and (3) glycated hemoglobin (HbA1c)
progression since index date.
In the first analysis, all insulin-naı¨ve patients
which initiated a therapy with GLP-1 receptor
agonists were observed for 12 months. In a
multivariable Cox regression analysis taking
into account possible confounding variables
available in the database (age, gender,
comorbidities and previous/concomitant
medications), we analyzed whether 6-month
NP with GLP-1 was associated with early insulin
therapy initiation (any insulin) in observed
patients until end of the 12th month.
In the second analysis, we determined in a
multivariable logistic regression analysis
whether 6-month NP with therapy with GLP-1
receptor agonists (gap[90 days) was associated
with a higher probability of experiencing an
acute hospitalization with T2DM as main
diagnosis (ICD 10 E11.-/E16.0/E16.1/E16.2) in
the second 6 months of the observational
period. Please note that in this analysis all
patients available in the German dataset were
included, whereas only a subsample of CPRD
T2DM patients for whom hospitalization data
were available (Hospital Episode Statistics) were
included in the UK analysis.
In the third analysis, we only included T2DM
patients which started a therapy with GLP-1
receptor agonists and had at least three HbA1c
values documented: at baseline (last value
measured before index date), 6–9 months after
index date, and 12–18 months after index date.
If more than one value in these periods was
available, we used the mean value. Change of
HbA1c was compared between patients having
continued their therapy with GLP-1 receptor
agonists after 6 months versus those having
discontinued their therapy at this time.
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Statistical Analysis
Discontinuation rates in patient subgroups
(GLP-1: OD/BID) were depicted using
Kaplan–Meier curves, significance of differences
between discontinuation rates was tested using
log-rank tests. To assess any factors predicting
discontinuation of therapy with GLP-1 receptor
agonists and insulin initiation, we did
multivariable Cox regression analyses; for
assessment of factors associated with
T2DM-hospitalization we did a multivariable
logistic regression analysis. The models were
estimated based on a backward elimination
methodology. All factors not reaching a p value
\0.1 were excluded in a stepwise procedure
(except age, gender and CCI, which remained in
the models as fixed independent variables even if
they did not reach statistical significance).
Finally, factors reaching a p \0.05 were
interpreted as statistically significant. All
reported p values were two-sided, and 95%
confidence intervals (CIs) were calculated for
hazard ratios (HRs)/odds ratios (ORs). Patients
with missing data were excluded from the dataset.
Descriptive evaluations were done with
Microsoft SQL Server 2008 and Microsoft Excel
2010 (Microsoft, Redmond, United States). All
other statistical analyses were done with SPSS
17.0 (IBM, Armonk, United States).
Compliance with Ethics Guidelines
Due to the non-interventional, retrospective
nature of the present study and the analysis of
an anonymized dataset, no ethical review of
this study was necessary. However, the study
was evaluated by a scientific steering committee
to which all the authors belonged as well as by
internal scientific committees belonging to the
data owners, the AOK PLUS and CPRD (CPRD
Protocol Approval Number: 14_022).
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
T2DM Samples
In the UK sample, 1905 T2DM patients started
a treatment with GLP-1 receptor agonists
during the observation period (mean age:
55.5 years, 47.2% female). In the German
sample, 1627 T2DM patients started a
treatment with GLP-1 receptor agonists (mean
age: 56.6 years, 51.4% female). Out of the total
samples, subsets including 1744 UK and 1349
German patients were determined eligible for
the adherence analysis. The remaining patients
(UK: 8.5%; Germany: 17.1%) discontinued
their therapy after only a single prescription.
Main patient characteristics are shown in
Table 1.
Background anti-diabetic medications
(6 months prior to index date) of the overall
sample of GLP-1 starters included: no
anti-diabetic medication in 2.2% of observed
UK patients and 10.9% of observed German
patients, insulin monotherapy in 3.1% UK and
6.6% German patients, metformin and/or SU
and/or DPP-4 inhibitors in 71.2% UK and 57.2%
German patients, and combination therapy
with Oral Diabetic Drugs (OAD) (metformin
and/or SU and/or DPP-4 inhibitors) and any
insulin in 23.5% UK and 25.4% German
patients.
During the 12-months observational period
after start of therapy with GLP-1 receptor
agonists (index date), 1.8% (UK) and 5.7%
(German) of the patients received no
concomitant anti-diabetic medication, 3.9%
and 4.8% of the UK and German patients,
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respectively, received at least one type of
insulin, 63.6% of UK and 61.7% of the
German patients received metformin and/or
SU and/or DPP-4 inhibitors and 30.7% of the
UK and 27.8% of German patients were
concomitantly treated with a combination
therapy of OAD (metformin and/or SU and/or
DPP-4 inhibitors) and any insulin.
In the UK, based on the 1905 T2DM patients
initiating therapy with GLP-1 receptor agonists,
56.8% received an OD treatment with GLP-1
receptor agonists until end of observational
period or observed NP (whichever occurred
first), 28.6% received a BID treatment, and
14.5% switched between OD and BID in the
observational period (5.8% from OD to BID and
61.4% from BID to OD and 32.9% more than
once). In German data, based on 1627 T2DM
starters of therapy with GLP-1 receptor agonists,
72.5% received an OD treatment, 18.1%
received a BID treatment, and 9.3% switched
between OD and BID (40.8% from OD to BID
and 35.5% from BID to OD and 23.7% more
than once).
Assessment of Treatment Persistence
The results of the persistence analysis of
treatment with GLP-1 receptor agonists are
presented in Figs. 2 and 3 and Table 2.
Percentage of NP (gap [90 days) patients after
12 months was 29.5% in the UK and 36.4% in
Germany; of these patients, 17.1% (5.0% of all
patients) in the UK and 33.9% (12.3% of all
patients) of the German patients received only a
single GLP-1 prescription. In both countries,
persistence was significantly better for OD
compared to BID therapy with GLP-1 receptor
agonists (Fig. 3): 72.8% (OD) versus 63.9% (BID)
in UK (p\0.001) and 63.7% (OD) versus 55.3%
(BID) in Germany (p\0.010). Table 2
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including a sensitivity analysis using a
[180 days treatment gap.
Assessment of Treatment Adherence
Overall, 12-month MPR for therapy with GLP-1
receptor agonists in the analyzed UK and
German T2DM samples was 76.0% and
73.9%, respectively. Table 3 describes the
results of the adherence analysis of treatment
with GLP-1 receptor agonists which was done
during periods of general treatment
continuation (no gaps [90 days) only. Mean
MPRs in the UK analysis were 88.6% for GLP-1
(all patients), 88.2% for OD GLP-1, and 89.3%
for BID GLP-1. Respective numbers for the
German analysis were 89.7% for GLP-1 (all
patients), 90.0% for OD GLP-1, and 89.4% for
BID GLP-1. Adherence observed with OD
therapy with GLP-1 receptor agonists was
similar to BID therapy with GLP-1 receptor
agonists in both countries. Based on a NA
definition of MPR \80%, the percentage of
patients affected by NA were 20.2%/20.0%/
20.5% (all patients/OD/BID) in the UK sample,
and 19.9%/19.2%/21.8% (all/OD/BID) in the
German sample.
Assessment of Predictors
of Discontinuation of Therapy with GLP-1
Receptor Agonists
To be able to assess the influence of the specific
treatment regimen with GLP-1 receptor agonists
(OD versus BID), only patients who did not
switch between BID and OD were included in
this analysis (UK: 1628 patients; German: 1475
patients).
Fig. 2 Kaplan–Meier curves for percentage of T2DM
patients persistent to their therapy with GLP-1 receptor
agonists. The ﬁgure describes percentage of T2DM still
persistent (no gap[90 days) to their therapy with GLP-1
receptor agonists over time (12 months) with regards to
UK-T2DM and GER-T2DM patients having started a
therapy with GLP-1 receptor agonists. T2DM type 2
diabetes mellitus, GLP-1 glucagon-like peptide-1, UK
United Kingdom, GER Germany
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In the Cox regression analysis, age or gender
of patients as well as their CCI were not
significantly associated with discontinuation
of therapy with GLP-1 receptor agonists in the
UK T2DM sample (Fig. 4). Predictors of early NP
were injection frequency (HR = 1.431, related
to BID versus OD; 95% CI 1.19–1.71), no
antidiabetic medication before index date
(HR = 3.439; 95% CI 1.61–7.36), and number
of received anti-diabetic agents in the 180 days
pre-/post index date (HR = 1.193, referring to
values between 0 and 4; 95% CI 1.06–1.34).
In German patients, results for age and
gender were similar to UK, however, a higher
CCI was associated with a higher probability of
early GLP-1 NP (HR = 1.051; 95% CI 1.00–1.10).
As in the UK, a BID treatment was associated
with a higher probability to discontinue a
treatment with GLP-1 receptor agonists earlier
than an OD treatment (HR = 1.314; 95% CI
1.08-1.60).
Assessment of NP-Related Outcomes
We identified 1398 (73.4%) UK and 1107
(68.0%) German insulin-naı¨ve patients having
started a therapy with GLP-1 receptor agonists
during our inclusion period. In multivariable
Cox regression analyses using time until insulin
initiation as dependent variable, among other
variables (number of additionally received
anti-diabetic agents, visit to diabetologists,
retinopathy, neuropathy, diuretics use, female
gender), NP to treatment with GLP-1 receptor
Fig. 3 Kaplan–Meier curves for percentage of persistent
GLP-1 patients during 12 months after therapy initiation.
The ﬁgure describes percentage of T2DM patients having
started a therapy with GLP-1 receptor agonists (four
groups: UK- and GER-T2DM patients having started
either an OD/BID therapy with GLP-1 receptor agonists)
being still persistent (no gap[90 days) with therapy over
time (12 months). Patients having switched their therapy
with GLP-1 receptor agonists between OD and BID were
excluded. GLP-1 glucagon-like peptide-1, T2DM type 2
diabetes mellitus, UK United Kingdom, GER Germany,
OD once daily, BID twice daily
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agonists after 6 months (treatment gap[90 days)
was significantly associated with earlier insulin
initiation (HR: 2.664 for UK (95% CI 2.11–3.35)
and 2.755 for German patients (95% CI
2.25–3.37).
In the multivariable logistic regression
analysis using T2DM-related hospitalizations
during the last 6 months of the observational
period as dependent variable, all German GLP-1
starters (1627 patients) could be considered,
whereas in the UK only 320 patients with
availability of hospital data could be analyzed.
In both countries, NP to therapy with GLP-1
receptor agonists after 6 months (treatment gap
[90 days) was not significantly associated with
the probability to experience a diabetes-related
hospitalization.
For the third analysis describing progression
of HbA1c values since initiation of treatment
with GLP-1 receptor agonists, 520 UK patients
and 252 German patients newly initiating a
therapy with GLP-1 receptor agonists and
having all required HbA1c data available were
analyzed. Patients persistent to therapy with
GLP-1 receptor agonists showed a higher mean
relative decrease in HbA1c after 6–9 months
compared to NP patients (UK: -6.5% versus
-4.7%; German: -4.4% versus -1.0%);
however, these differences were not
statistically significant. Initial differences in
HbA1c were smaller (more moderate) or even
changed direction after 12–18 months (UK:
-5.4% versus -7.8%; German: -4.7% versus
-2.9%).
Fig. 4 Factors associated with early GLP-1 discontinua-
tion. The ﬁgure shows the results of the multivariable Cox
regression analyses with regards to independent factors
inﬂuencing early GLP-1 discontinuation (4a GER, 4b UK).
GLP-1 glucagon-like peptide-1, UK United Kingdom, GER
Germany, CI conﬁdence interval, CCI Charlson Comor-
bidity Index, BID twice daily
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DISCUSSION
Study Objectives and Main Results
We aimed to assess the level of persistence and
adherence to therapy with GLP-1 receptor
agonists in T2DM patients and to identify
predictors/outcomes of GLP-1 discontinuation.
One of the main advantages of this study is use
of two different databases from two European
countries, but using the same methodology to
calculate treatment persistence/adherence in
the analyses.
Our data show that patients receiving
therapy with GLP-1 receptor agonists are
broadly similar in their demographic
characteristics in the UK and Germany. The
main difference was the CCI, with German
GLP-1-patients having greater morbidity at a
similar age. This is likely related to the existing
therapy advice of the German Federal Joint
Committee, which restricts reimbursement for
GLP-1s in healthier patients, recommending
GLP-1 use mainly in T2DM patients with
insulin resistance and a Body Mass Index (BMI)
[30 [26].
However, pre-index anti-diabetic therapy
differed between the countries. Generally,
therapy with GLP-1 receptor agonists seems to
be prescribed as second or third-line therapy in
UK patients whereas it is chosen as first-line
therapy in at least 10% of the German T2DM
patients. Concomitant anti-diabetic medication
patterns were similar across countries.
Our analysis identified a large percentage of
patients having discontinued their therapy with
GLP-1 receptor agonists after 12 months. In the
UK, this percentage was slightly lower than in
Germany (29.6% versus 36.6%). In a sensitivity
analysis using a treatment gap of [180 days
instead of 90 days, NP rates were lower, as
expected, but still with a slightly higher NP
rate in Germany. This corresponded with a
slightly higher overall 12-month MPR in the UK
compared to Germany in the overall sample of
persistent and non-persistent patients. Finally,
percentage of patients affected by NA during
general continuation of treatment with GLP-1
receptor agonists was very similar across the
countries (20.2% in UK versus 19.9% in
Germany). The observed persistence
differences between UK and German patients
may be related to different patient
characteristics, different medication patterns
before therapy with GLP-1 receptor agonists
started, different concomitant medication
patterns, or the fact that we could not exclude
hospitalization days from analysis in the UK
dataset. Moreover, probably more important,
the UK CPRD database documents all
prescriptions issued by physicians whereas the
German claims database documents issued
prescriptions having been filled in pharmacies
only. Finally, in the UK ‘‘repeated prescriptions’’
which can be supplied for a certain period of
time on a regular basis without having to be
seen by a physician each time can be normally
authorized for a period of 6–12 months. It can
be assumed that repeated prescriptions lead to a
certain over-statement of treatment persistence
because a refill practice like repeated
prescriptions is not known in Germany.
Therefore, taking all these factors into
account, we conclude that GLP-1 related
persistence/adherence is similar across the UK
and Germany.
Our estimates describing persistence/
adherence of starters of therapy with GLP-1
receptor agonists in UK and Germany are
generally consistent with numbers presented
in earlier studies. In a US analysis, a 12-month
MPR of 68% for BID therapy with GLP-1
receptor agonists was reported, related to
patients having received at least 2
120 Diabetes Ther (2016) 7:105–124
prescriptions [21]. Another US claims analysis
found that, after adjusting for confounding
factors, patients receiving OD liraglutide were
11% more adherent than patients receiving BID
exenatide; mean MPRs were 69.7% OD GLP-1
and 64.4% for BID GLP-1 [22]. A third US claims
data analysis compared adherence between BID,
OD and once-weekly therapy with GLP-1
receptor agonists. It reported a higher
unadjusted MPR for once-weekly therapy
(78.3%), compared to BID (50.0%) or OD
therapy (68.3–76.1% depending on dosage)
[23]. The only known European-based study
which analyzed adherence/persistence to
therapy with GLP-1 receptor agonists reported
a 12-month therapy discontinuation rate of
32.2% to BID treatment [27]. So, generally, our
numbers indicate a slightly higher persistence/
adherence than shown in previous studies. We
confirm the conclusion of earlier studies that a
BID treatment with GLP-1 receptor agonists is
discontinued sooner than an OD treatment
with GLP-1 receptor agonists. Moreover, our
high numbers of patients (5.0% of all observed
patients in the UK and 12.3% of all observed
German patients) not having received a second
GLP-1 prescription indicate that there seems to
be an initial ‘‘trial period’’ in treatment with
GLP-1 receptor agonists, which may be due to
the common gastrointestinal adverse events of
these drugs [28].
A specific characteristic of our study is that it
differentiated between treatment adherence
and treatment persistence. We think that
persistence and adherence to treatment are
different real-world phenomena which may be
caused by different factors and which may lead
to different conclusions. However, in most of
the publications known to the authors of this
study, adherence and persistence are analyzed
jointly so that reported percentage of NA
patients still includes patients who
discontinued their therapy during a
pre-defined observational period. To allow
comparison of our reported numbers with
those in known publications, we both reported
the overall MPR as well as specific persistence/
adherence measures.
In terms of outcomes related to GLP-1
discontinuation, our analysis shows that
delayed HbA1c decrease and early insulin
initiation are probably associated with NP to
therapy with GLP-1 receptor agonists. However,
because insulin therapy is a recommended
follow-up treatment after failure/
discontinuation of therapy with GLP-1
receptor agonists, it was very difficult to assess
the association between GLP-1 continuation
and HbA1c decrease. Furthermore, we did not
find any association between T2DM-related
hospitalizations and discontinuation of
therapy with GLP-1 receptor agonists which
may be explained by the comparatively young
age of GLP-1 starters in our samples, but could
also be due to effective and safe follow-up
treatments and a short observational period
we had available.
Limitations
We acknowledge several limitations of our
analysis. Due to the longitudinal limitations of
our dataset at the time of these analyses, we
could only observe a period of 12 months after
start of therapy with GLP-1 receptor agonists.
We defined NP as treatment gap [90 days
and NA as MPR \80%. While these thresholds
are widely used in adherence/persistence
literature; they have hardly been clinically
validated so far [15]. We dealt with this
weakness by reporting results of a sensitivity
analysis using a[180 days gap as NP definition
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and using different MPR-thresholds of 70%,
80%, and 90%.
In our multivariable analyses, we could not
include all variables of interest. Patient
characteristics not associated with specific
diagnoses and/or prescription patterns like
smoking/non-smoking behavior, specific GFR
values [29] or level of physical activity [30] were
not available.
In our analysis of HbA1c progression over
time and T2DM-related hospitalizations, we
could not include all patients because of data
limitations. Moreover, time to insulin initiation
may be a biased clinical outcome in the German
analysis because, based on the mentioned
treatment recommendations in Germany, only
patients with insulin resistance and a BMI[30
are recommended for GLP-1 use.
We concluded that OD treatment is
associated with a higher persistence than BID
treatment with GLP-1 receptor agonists.
However, since exenatide is known to evoke
adverse gastrointestinal symptoms more
frequently than liraglutide, these persistence
differences could also be due to the medicine
instead of the intake frequency.
Finally, due to our large sample size, some
independent variables may have exerted a
statistical influence but, due to low hazards/
odds ratios, not in a clinically meaningful way.
CONCLUSIONS
AND IMPLICATIONS FOR PRACTICE
NP to treatment with GLP-1 receptor agonists in
both UK and Germany seems to be comparable.
Persistence to OD treatment with GLP-1 receptor
agonists is higher than to BID treatment with
GLP-1 receptor agonists across the UK and
Germany. Discontinuation of treatment with
GLP-1 receptor agonists may warrant that
physicians closely follow patients on GLP-1s to
ensure continuity of anti-diabetic treatment.
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